BioSpace News Archive

Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Products Clinical Results in GvHD Studies May be Beneficial in COVID-19 and CAR-T Cytokine Storm manifestations [18-May-2020] TEL AVIV, Israel , May 18, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative tec

- OCS-01 meets primary endpoints demonstrating superior efficacy and safety vs vehicle in the treatment of inflammation and pain following cataract surgery with a once-daily regimen - SKYGGN is the second positive trial with OCS-01 highlighting its potential for treating both front-of-the-eye and retinal diseases such as DME - Positive results validate the Solubilizing NanoParticle (SNP) formulation technology in developing topical treatments for front-of-the-eye with less fr

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announ

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic derm

Ashvattha Therapeutics , a biotech company focused on novel dendrimer-based therapies targeting unmet medical needs in ocular, inflammatory diseases, and oncology, has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , held June 22-24, 2020. Full details of the virtual presentation are as follows: Abstract Title: Selective targeting of immunosuppr

Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 Company reported in March 2020 that FDA had also provided positive feedback on the pivotal trial design GAINESVILLE, Fla.--( BUSINESS WIRE )-- Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pic

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced President and Executive Director Darren Lui will share insight into the company’s recent developments and upcoming milestones during an investor webinar on Tuesday, May 19, 2020 at 4:00 p.m. ET.

As further evidence of the strong industry response to a potential new paradigm in the treatment of cancer, Varian (NYSE: VAR) today announced that Proton Therapy Pte., Ltd. ( http://www.proton.sg/ ) in Sin

JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company’s Australian Phase I Clinical Trial of JHL1266 in healthy subjects. The Three-A

ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140